This article was written by
Experience: Former Fund Manager of a Hedge Fund focused on Biotech and Pharmaceutical companies. Over 20 years in the BioPharma Industry, including various roles on the commercial side. Investing Goal: Outperform the XBI each year by identifying and then investing in assets that should change the current standard of care in a particular disease. Portfolio sizing: Typically, high risk/high reward plays will be acquired up to 2 percent positions in my portfolio. More moderate risk/moderate reward positions may accumulate up to 4-5 percent, and then highest convictions may top out ~10 percent. Occasionally, I do buy large and/or mega-caps, but rarely. Risk Management: Options may be used to both augment and protect positions and/or in-lieu of holding actual shares. Active trading is used to continuously improve positions. Timing: I will always seek to provide a time frame for my investment thesis, with updates typically as new data is available. All active holdings will get an update though at least once a quarter. Articles: I love the biotech industry and want to continue to help others to understand its potential and limitations. I am a straight-shooter; therefore, my articles will share my thoughts on an asset and/or disease state as well as spell out my reasons for why I invested in a company or would not. If you are looking for fluffy charts, tables and graphs...they typically can be found on a company's website and/or one of the "Big-House’s" research reports. Please keep in mind that this is Biotech. Most drugs fail in development, and many that are approved do not go on to commercial success. On top of that, there are external forces including regulatory, government and political that can negatively impact even the best investment stories. This is one of the main reasons that I seek Pivotal Biotech data, events, outcomes and trends to improve the likelihood of my investing success. Though successes are more fun to talk about, I will also attempt to deconstruct failures as I too continue to learn from an ever-changing, fast-paced and potentially volatile sector. I strongly encourage anyone reading my articles and certainly anyone investing money to complete their own due diligence.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of CERE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
